Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock

Cantor Fitzgerald reiterated its Overweight rating for Bicara Therapeutics (BCAX), citing confidence in ficerafusp's ability to achieve deep tumor shrinkage in over 80% of responders, potentially correlating with improved survival metrics. This positive assessment contrasts with results from a MRUS study showing less significant tumor shrinkage. Despite positive Phase 1/1b trial data showing a 64% objective response rate in HPV-negative patients, Bicara's stock recently declined, though analysts from Stifel, TD Cowen, and H.C. Wainwright maintain Buy ratings with price targets ranging from $41 to $48, anticipating key data updates at the upcoming ASCO meeting.

Analysis

Cantor Fitzgerald has reiterated an Overweight rating for Bicara Therapeutics Inc. (NASDAQ: BCAX), which is currently trading at $9.25, citing significant potential upside with analyst targets ranging from $8 to $48. This confidence is primarily driven by ficerafusp, Bicara's therapeutic candidate, which has demonstrated the ability to achieve deep responses, with over 80% of responders experiencing more than 80% tumor shrinkage—a metric suggested to correlate with improved durability, progression-free survival (PFS), and overall survival (OS). This efficacy is contrasted favorably with a MRUS study where fewer than 50% of responders achieved similar results. Despite positive interim data from its Phase 1/1b trial of ficerafusp alfa combined with pembrolizumab for head and neck squamous cell carcinoma (highlighting a 64% objective response rate in HPV-negative patients, a median PFS of 9.8 months, and a 12-month overall survival rate of 61%), Bicara’s stock recently experienced a significant drop. However, analysts from Stifel (price target $48), TD Cowen, and H.C. Wainwright (price target $41) maintain Buy ratings, emphasizing the company's favorable risk/reward profile and viewing the upcoming ASCO meeting as a key event for anticipated data updates that could further validate ficerafusp's potential.

Key Decisions for Investors

• Investors should consider the current valuation of Bicara Therapeutics (BCAX) relative to the strong clinical data for ficerafusp and consistent analyst support, particularly following the recent stock price decline which may present a dislocation.
• Closely monitor Bicara's presentation at the upcoming ASCO meeting, as new data on ficerafusp could be a significant catalyst affecting the stock's trajectory and analyst outlooks.
• Evaluate the wide analyst price target range ($8-$48) against the current trading price ($9.25) to assess the potential risk/reward profile, factoring in the inherent volatility and catalyst-driven nature of the biotech sector.